- Home
- CELU vs DXR Comparison
CELU vs DXR Comparison
Compare CELU & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- DXR
- Stock Information
- Founded
- CELU 2016
- DXR 1970
- Country
- CELU United States
- DXR United States
- Employees
- CELU N/A
- DXR N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- CELU Health Care
- DXR Health Care
- Exchange
- CELU Nasdaq
- DXR Nasdaq
- Market Cap
- CELU 42.2M
- DXR 40.3M
- IPO Year
- CELU N/A
- DXR N/A
- Fundamental
- Price
- CELU $1.63
- DXR $7.92
- Analyst Decision
- CELU
- DXR Strong Buy
- Analyst Count
- CELU 0
- DXR 1
- Target Price
- CELU N/A
- DXR $25.00
- AVG Volume (30 Days)
- CELU 102.4K
- DXR 9.1K
- Earning Date
- CELU 12-06-2024
- DXR 01-01-0001
- Dividend Yield
- CELU N/A
- DXR N/A
- EPS Growth
- CELU N/A
- DXR 86.16
- EPS
- CELU N/A
- DXR 0.11
- Revenue
- CELU $48,200,000.00
- DXR $119,714.00
- Revenue This Year
- CELU N/A
- DXR N/A
- Revenue Next Year
- CELU $233.89
- DXR N/A
- P/E Ratio
- CELU N/A
- DXR $74.89
- Revenue Growth
- CELU 225.94
- DXR N/A
- 52 Week Low
- CELU $1.00
- DXR $6.55
- 52 Week High
- CELU $5.69
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- CELU 46.69
- DXR 48.18
- Support Level
- CELU $1.64
- DXR $8.02
- Resistance Level
- CELU $2.40
- DXR $8.24
- Average True Range (ATR)
- CELU 0.20
- DXR 0.40
- MACD
- CELU 0.01
- DXR -0.03
- Stochastic Oscillator
- CELU 17.20
- DXR 0.00
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.